Edwards Lifesciences Corp

Latest Results (21.10.2025):

Edwards Lifesciences Corp reported strong financial results for the fourth quarter and full year ended December 31, 2024. The company achieved significant sales growth across all product groups, driven by robust performances in TAVR and TMTT segments. Edwards maintained a solid financial position with optimistic guidance for 2025, highlighting continued innovation and expansion in structural heart therapies.

Revenue Growth

Q4 sales increased by 9% to $1.39 billion, surpassing expectations with strong performance across all product lines. For the full year 2024, global sales reached $4.1 billion, marking a 6% year-over-year growth.

TAVR Performance

Transcatheter Aortic Valve Replacement (TAVR) sales grew by 6% in Q4 to $1.04 billion, or 5% on a constant currency basis. The U.S. SAPIEN 3 Ultra RESILIA platform continued to lead the market, while international sales benefited from the launch of SAPIEN 3 Ultra RESILIA in Europe.

TMTT Growth

Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a remarkable 88% increase in Q4 sales to $105 million, contributing significantly to the company’s overall growth. Full-year sales reached $352 million, up 78% year-over-year, driven by the PASCAL repair system and EVOQUE tricuspid replacement system.

Earnings Per Share

For Q4, Edwards reported an EPS of $0.581 and an adjusted EPS of $0.59, reflecting strong top-line performance. The company maintained its full-year 2025 adjusted EPS guidance of $2.40 to $2.50.

Clinical Trials and Innovations

Edwards presented results from the EARLY TAVR and TRISCEND II clinical trials, showcasing groundbreaking advancements in structural heart treatments. The EARLY TAVR trial, the largest of its kind, is expected to support FDA approval for treating asymptomatic severe aortic stenosis patients by mid-year.

Financial Outlook

The company reiterated its 2025 sales growth guidance of 8% to 10% on a constant currency basis and anticipates continued expansion of its structural heart therapy portfolio beyond 2026. Edwards expects total sales for Q1 2025 to be between $1.35 and $1.43 billion, with an adjusted EPS of $0.58 to $0.64.

CEO’s Statement

Bernard Zovighian, CEO of Edwards Lifesciences, emphasized the company's strong position at the end of 2024 and expressed optimism about future growth drivers, including innovations in TAVR, Mitral and Tricuspid therapies, and emerging opportunities in Structural Heart Failure and Aortic Regurgitation.